Focus Partners Wealth
LTRN icon

Focus Partners Wealth’s Lantern Pharma LTRN Stock Holding History

Focus Partners Wealth’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.1K Sell
15,432
-550
-3% -$1.54K ﹤0.01% 2610
2025
Q4 		$48.4K Buy
+15,982
New +$59.5K ﹤0.01% 2606

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Focus Partners Wealth's LTRN Position: Q1 2026 in Review

Focus Partners Wealth reduced its Lantern Pharma (LTRN) stake by 3.4% in Q1 2026, selling an estimated $1.54K and leaving 15,432 shares worth $21.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2610.

Focus Partners Wealth first reported a position in LTRN in Q4 2025 and has held it in 2 quarters since. The position peaked at $48.4K in Q4 2025. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Focus Partners Wealth held 15,432 shares of Lantern Pharma worth $21.1K as of Q1 2026.
  • Focus Partners Wealth sold 550 Lantern Pharma shares in Q1 2026, an estimated $1.54K.
  • Lantern Pharma made up ﹤0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #2610 holding.
  • Focus Partners Wealth first reported a position in Lantern Pharma in Q4 2025 and has held it in 2 quarters since.
  • Focus Partners Wealth's Lantern Pharma position peaked at $48.4K in Q4 2025.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.